Gilead Wins CHMP Backing for Trodelvy® in First-Line Metastatic TNBC Treatment Gilead Sciences has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of Trodelvy…
DiaMedica Therapeutics announced that it has reached approximately 75% enrollment in its ReMEDy2 Phase 2/3 acute ischemic stroke trial, marking a key development milestone in the study. DiaMedica Therapeutics Inc. announced a significant development in its late-stage clinical program for…
Texas Cancer Institute Implements Kallisio Technologies Stentra™ as Standard-of-Care for Precision Radiation Therapy After Successful Clinical Pilot Kallisio announced that the Texas Cancer Institute has officially transitioned its use of the company’s Stentra™ system from a pilot evaluation phase into…
Atrandi Biosciences Enhances Executive Team to Drive International Growth of Its Innovative Single-Cell Technology Atrandi Biosciences has expanded its executive and governance leadership team with the appointment of Sam Ropp as Chief Commercial Officer and Susan Tousi as Chairman of…
TRIANA Biomedicines Appoints Mohan Bala as COO and Expands Scientific Advisory Board With Industry Experts TRIANA Biomedicines has announced a series of major leadership and scientific advisory appointments as the company continues expanding its molecular glue degrader platform and advancing…
Endospan Completes Acquisition by Artivion, Inc. After FDA Approval of the NEXUS® Aortic Arch System Endospan has announced the completion of its acquisition by Artivion in a deal that significantly strengthens Artivion’s position in the global aortic repair market and…
BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension in the U.S. AstraZeneca has announced that the U.S. Food and Drug Administration has approved BAXFENDY for the treatment of hypertension in adults whose blood pressure remains inadequately controlled…
Natera Receives FDA Approval for Signatera CDx as First Blood-Based MRD Companion Diagnostic in Muscle-Invasive Bladder Cancer Natera announced that the U.S. Food and Drug Administration has approved Signatera CDx as a companion diagnostic for use alongside adjuvant atezolizumab, marketed…
Kariya and NeuraLight Collaborate to Evaluate Brain Effects of Next-Generation GLP-1 Therapies Kariya Pharmaceuticals and NeuraLight have announced a strategic partnership aimed at advancing the development of next-generation brain-focused GLP-1 therapies for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.…
Ionis and Biogen Report Promising Phase 2 Results for Tau-Targeting Alzheimer’s Therapy Diranersen Ionis Pharmaceuticals and Biogen have announced encouraging topline findings from the Phase 2 CELIA clinical study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy designed to…
BeOne Medicines’ BEQALZI™ Receives U.S. FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines has announced that the U.S. Food and Drug Administration has granted accelerated approval to BEQALZI for the treatment of adult…
AskBio to Present New Gene Therapy and AAV Manufacturing Research at ASGCT 2026 AskBio, a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, has announced that it will present six scientific sessions at the…